Orazio Caffo, MD, discusses the CHEIRON trial findings and their implications on the treatment paradigm in metastatic castration-resistant prostate cancer.
Original Article: Enzalutamide/Docetaxel Combo Improves PFS, But Not OS in Frontline mCRPC